DSC Technologies

DSC Technologies (Louisville, KY) is developing a point-of-care blood plasma assay to distinguish between Type I and Type II heart attacks. Toponin biomarker assays are the current standard diagnostic, however several thousand patients are misdiagnosed each year with potentially dangerous ramifications.

DSC Technologies (Louisville, KY) is developing a point-of-care blood plasma assay to distinguish between Type I and Type II heart attacks. Toponin biomarker assays are the current standard diagnostic, however several thousand patients are misdiagnosed each year with potentially dangerous ramifications.